Swedish Orphan Biovitrum AB BIOVF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $46.00
- Day Range
- $45.72–45.72
- 52-Week Range
- $34.88–49.03
- Bid/Ask
- $27.54 / $61.23
- Shares Outstanding
- 348.00M
- Market Cap
- $15.81B
- Volume/Avg
- 110 / 3,189
Key Statistics
- Price/Earnings (Normalized)
- 22.80
- Price/Sales
- 4.91
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 2,119
- Website
- https://www.sobi.com
Competitors
Valuation
|
Metric
|
BIOVF
|
RHHBY
|
4502
|
|---|---|---|---|
Price/Earnings (Normalized) | 22.80 | 21.09 | 53.41 |
Price/Book Value | 3.67 | 9.39 | 1.33 |
Price/Sales | 4.91 | 4.84 | 2.17 |
Price/Cash Flow | 14.81 | 15.16 | 12.13 |
Price/Earnings
BIOVF
RHHBY
4502
Financial Strength
|
Metric
|
BIOVF
|
RHHBY
|
4502
|
|---|---|---|---|
Quick Ratio | 0.55 | 0.80 | 0.54 |
Current Ratio | 0.88 | 1.23 | 1.14 |
Interest Coverage | 2.70 | 13.49 | 0.07 |
Quick Ratio
BIOVF
RHHBY
4502
Profitability
|
Metric
|
BIOVF
|
RHHBY
|
4502
|
|---|---|---|---|
Return on Assets (Normalized) | 9.37% | 15.81% | 5.53% |
Return on Equity (Normalized) | 17.61% | 48.77% | 11.34% |
Return on Invested Capital (Normalized) | 13.82% | 23.90% | 7.74% |
Return on Assets
BIOVF
RHHBY
4502
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|t<#bK>!V | LOCK|>>DC$ | $71B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|T?&##Zm | LOCK|P#!! | $47B | |||
| Haleon PLC ADR
HLN
| LOCK|<$%PmK$ | LOCK|>L? | $45B | |||
| Zoetis Inc Class A
ZTS
| LOCK|q&H!!T?^ | LOCK|xl | $34B | |||
| Viatris Inc
VTRS
| LOCK|cjTWC?y | LOCK|>JG | $21B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|&tH | LOCK|xZ& | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|dzNx%$% | LOCK|>^ | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|?z<@D@ | LOCK|sg | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|C$cKB> | LOCK|$M^>Y | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|c$f!<p# | LOCK|Kw | $2B |
United States